Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 4 Nasopharyngeal Carcinoma 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Head and Neck Neoplasms 2 Stomach Neoplasms 1 Resectable Pancreatic Cancer 1 Penile Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Glioma 1 Glioblastoma 1 Esophageal 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Advanced and/or Metastatic Solid Tumours 1 Advanced Esophageal 1 Adenocarcinoma 1

Interventions

Gemcitabine 27 Fluorouracil 25 Oxaliplatin 21 Cisplatin 19 Leucovorin 17 Bevacizumab 15 130-nm albumin-bound paclitaxel 13 Docetaxel 12 Capecitabine 12 Albumin-Bound Paclitaxel 12 Paclitaxel 11 Irinotecan 10 Carboplatin 9 pembrolizumab 7 Radiotherapy 6 Pemetrexed 6 Nivolumab 6 Erlotinib Hydrochloride 6 Cyclophosphamide 6 Trastuzumab 5 Ramucirumab 5 Ipilimumab 4 Everolimus 4 Crizotinib 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × nimotuzumab × Clear all

NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡